Opendata, web and dolomites

ENDFLU SIGNED

Evaluation of ratioNally Designed Influenza vaccines

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ENDFLU project word cloud

Explore the words cloud of the ENDFLU project. It provides you a very rough idea of what is the project "ENDFLU" about.

combination    assessing    construct    induces    expressed    india    combat    efficacy    dose    clade    cell    either    immunogenicity    surface    encode    compliant    world    vaccination    rational    worldwide    mice    safety    internal    advocacy    clinically    elicit    mva    gmp    infection    ferrets    pandemic    proteins    clinical    create    protective    scientific    hemagglutinin    fusions    generation    artificial    adoption    biophysical    stem    toward    achievements    optimized    immunity    na    combined    repository    demonstration    cross    expertise    biochemical    model    humoral    epitopes    encoding    complementary    chim    trial    functional    strategies    protein    endflu    ing    select    head    optimal    seeds    constructs    manufacturing    h5    rationally    human    optimize    conserved    nanoparticles    fueled    candidates    enter    manifestations    influenza    criteria    designed    formulation    polyepitope    followed    m2e    vaccine    broadly    mediated    indian    plan   

Project "ENDFLU" data sheet

The following table provides information about the project.

Coordinator
STIFTUNG TIERAERZTLICHE HOCHSCHULE HANNOVER 

Organization address
address: BUNTEWEG 2
city: HANNOVER
postcode: 30559
website: www.tiho-hannover.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 14˙444˙867 €
 EC max contribution 8˙646˙254 € (60%)
 Programme 1. H2020-EU.3.1.2. (Preventing disease)
 Code Call H2020-SC1-2019-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-04-01   to  2025-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STIFTUNG TIERAERZTLICHE HOCHSCHULE HANNOVER DE (HANNOVER) coordinator 1˙234˙225.00
2    CURVE CLINICAL BV NL (AMSTERDAM DUIVENDRECHT) participant 3˙364˙571.00
3    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 2˙342˙075.00
4    VIB BE (ZWIJNAARDE - GENT) participant 608˙750.00
5    UNIVERSITEIT UTRECHT NL (UTRECHT) participant 435˙707.00
6    LUNDS UNIVERSITET SE (LUND) participant 360˙925.00
7    ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE CH (LAUSANNE) participant 300˙000.00
8    COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH IN (NEW DEHLI) participant 0.00
9    INDIAN INSTITUTE OF SCIENCE IN (BANGALORE) participant 0.00
10    INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH THIRUVANANTHAPURAM IN (THIRUVANANTHAPURAM) participant 0.00
11    MANIPAL ACADEMY OF HIGHER EDUCATION IN (MANIPAL) participant 0.00
12    MYNVAX PRIVATE LIMITED IN (BANGLADORE) participant 0.00
13    SETH G S M COLLEGE AND K E M HOSPITAL DIAMOND JUBILEE SOCIETY IN (MUMBAI) participant 0.00
14    TRANSLATIONAL HEALTH SCIENCE AND TECHNOLOGY INSTITUTE IN (FARIDABAD) participant 0.00

Map

 Project objective

ENDFLU will develop three complementary next-generation influenza vaccination strategies for the world, fueled by the unique combined expertise of Indian and European partners in rational vaccine design and development: • Create a repository of pre-pandemic GMP-compliant MVA-based vaccine seeds, each encoding an influenza hemagglutinin (HA), based on European partners demonstration of clinical safety and cross-clade immunogenicity of MVA-H5. • Optimize and select protein- and MVA-based constructs developed by Indian and European ENDFLU partners, resulting in a rationally combined vaccine formulation that induces broadly protective humoral and cell-mediated immunity against all influenza manifestations. This will be advanced in a Phase I clinical trial and Controlled Human Infection Model (CHIM) study. • Pre-clinically advance other promising protein- and MVA-based constructs toward future development beyond ENDFLU. Constructs to elicit humoral immunity build on rationally-designed and optimized conserved epitopes of influenza surface proteins, HA stem- and HA head-nanoparticles, and NA-M2e fusions either as proteins or MVA expressed. Other MVA-based constructs to elicit cell-mediated immunity will encode conserved internal protein T cell epitopes, as an artificial polyepitope. The best candidates will be selected based on biochemical, biophysical, functional and manufacturing criteria, and immunogenicity and protective efficacy in mice and ferrets. The selected protein-based construct will enter a Part A Phase I clinical trial in India assessing safety, immunogenicity and optimal dose, to be combined with the selected MVA-based construct. This protein-MVA combination will enter a Part B Phase I clinical trial in the EU, assessing safety and immunogenicity, followed by the CHIM study. A dissemination and exploitation plan, and collaboration with key scientific advocacy organizations will facilitate the adoption of ENDFLU achievements to combat influenza worldwide.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ENDFLU" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ENDFLU" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.2.)

EMPOWER (2020)

European platforM to PromOte Wellbeing and HEalth in the woRkplace

Read More  

RISCC (2020)

RISK-BASED SCREENING FOR CERVICAL CANCER

Read More  

EXIMIOUS (2020)

Mapping Exposure-Induced Immune Effects: Connecting the Exposome and the Immunome

Read More